Washington University School of Medicine
This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-directed peptide vaccine plus checkpoint blockade.
Inclusion Criteria for All Patients: * Patients must be ≥4 and ≤25 years of age (inclusive) at the time of study enrollment * Metastatic Disease: Patients with M+ disease are eligible. * Adequate bone marrow function defined as: * ANC (Absolute neutrophil count) ≥ 1000/µl. * Platelets ≥ 75,000/µl. * Hemoglobin \> 8 g/dL. (may be supported) * Adequate renal function defined as: * Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m\^2 OR A serum creatinine based on age/gender as listed in the protocol. Note: The threshold creatinine values in this table were derived from the Sc…
Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.
Td 5 flocculation units, Lf
Administered intravenously
Administered orally
Arctuva estimate
Verify or correct the compensation shown for this listing.